TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19881230

Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balneotherapy
Number of subjects: 0
Study: 18844245

Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 58

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 58
Study: 16087825

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 mug once daily)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Alendronate (10 mg once daily)
Number of subjects: 203
Study: 11979503

Group type: EXPERIMENTAL
Intervention: Vitamin C (250 mg day(-1))
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Zinc (20 mg day(-1))
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 10332671

Group type: EXPERIMENTAL
Intervention: Teamwork intervention
Number of subjects: 85

Group type: COMPARATOR
Intervention: Attention control and standard care (combined comparison)
Number of subjects: 85
Study: 7831433

Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Dextrose infusion
Number of subjects: 9
Study: 3756055

Group type: EXPERIMENTAL
Intervention: Positive suggestions during general anaesthesia
Number of subjects: 91

Group type: COMPARATOR
Intervention: Noise during general anaesthesia
Number of subjects: 91

Group type: COMPARATOR
Intervention: Operating theatre sounds during general anaesthesia
Number of subjects: 91
Study: 29995670

Group type: EXPERIMENTAL
Intervention: Online EAC education (introductory webpage and 5-minute professional video)
Number of subjects: 2943

Group type: COMPARATOR
Intervention: Control group (no online EAC education)
Number of subjects: 2943
Study: 30144431

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg once daily for 6 months
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 26916176

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (subgroup 24-25 weeks)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo (subgroup 24-25 weeks)
Number of subjects: 523
Study: 26576619

Group type: EXPERIMENTAL
Intervention: Sodium polystyrene sulfonate (30 g orally once daily for 7 days)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 23650803

Group type: EXPERIMENTAL
Intervention: Early treatment group (acupuncture from the 7th to 14th day after surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Late treatment group (acupuncture from the 15th day after surgery)
Number of subjects: 60
Study: 21562201

Group type: EXPERIMENTAL
Intervention: Speaking in L2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Speaking in L1
Number of subjects: 0
Study: 19061971

Group type: EXPERIMENTAL
Intervention: Albinterferon alfa-2b 1200 microg every 4 weeks plus oral ribavirin
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Albinterferon alfa-2b 900 microg every 2 weeks plus oral ribavirin
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Albinterferon alfa-2b 1200 microg every 2 weeks plus oral ribavirin
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Albinterferon alfa-2b 1500 microg every 2 weeks plus oral ribavirin
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Albinterferon alfa-2b 1800 microg every 2 weeks plus oral ribavirin
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Albinterferon alfa-2b (various doses)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Albinterferon alfa-2b (1800 microg)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Previous nonresponders to pegylated interferon-alfa/ribavirin with genotype 1 infection
Number of subjects: 115
Study: 17029307

Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20 mg/day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mirtazapine 30-45 mg/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12773605

Group type: EXPERIMENTAL
Intervention: Critical time intervention program
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 96
Study: 10930159

Group type: COMPARATOR
Intervention: Comparison arm (no intervention)
Number of subjects: 1070

Group type: EXPERIMENTAL
Intervention: Intervention arm (syndromic treatment)
Number of subjects: 1070
Study: 9541340

Group type: EXPERIMENTAL
Intervention: Ibuprofen, 400 mg (n = 26)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (n = 31)
Number of subjects: 57
Study: 7995800

Group type: EXPERIMENTAL
Intervention: Speech/language impaired children
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control children
Number of subjects: 215
Study: 3057159

Group type: EXPERIMENTAL
Intervention: Penicillin (91 patients)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo (87 patients)
Number of subjects: 178
Study: 31244686

Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training (SCIT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Therapeutic Alliance Focused Therapy (TAFT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 63
Study: 28968793

Group type: EXPERIMENTAL
Intervention: SB4 (50 mg/week)
Number of subjects: 596

Group type: COMPARATOR
Intervention: ETN (50 mg/week)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: SB4
Number of subjects: 596

Group type: COMPARATOR
Intervention: ETN
Number of subjects: 596
Study: 25553599

Group type: EXPERIMENTAL
Intervention: Rapeseed-sterol margarine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Tall-sterol margarine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 58
Study: 24359122

Group type: EXPERIMENTAL
Intervention: Adhesive polyurethane foam dressing
Number of subjects: 820

Group type: COMPARATOR
Intervention: Adhesive hydrocolloid dressing
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Safety evaluation
Number of subjects: 820
Study: 20837625

Group type: EXPERIMENTAL
Intervention: 5 monthly 60‐minute sessions at a recreation center (group physical activity, goal setting)
Number of subjects: 72

Group type: COMPARATOR
Intervention: 2 standard‐of‐care clinic visits plus a group discussion
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Parents who gained BMI
Number of subjects: 72
Study: 19024037

Group type: EXPERIMENTAL
Intervention: Increased fruit and vegetable intake
Number of subjects: 0
Study: 16567437

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced sonography
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 3-phase computed tomography (CT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional angiography (reference standard)
Number of subjects: 29
Study: 14498755

Group type: EXPERIMENTAL
Intervention: Omapatrilat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pure ACE inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11012475

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 500 mg o.d. for 6 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 65
Study: 8816574

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Copolymer‐1 (20 mg)
Number of subjects: 0
Study: 1287303

Group type: EXPERIMENTAL
Intervention: Pre-hospital thrombolysis with streptokinase (500,000 U) and heparin (10,000 U) administered before hospital admission (Group 1)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional therapy (Group 3)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Pre-hospital thrombolysis with streptokinase and heparin administered after hospital admission (Group 2)
Number of subjects: 150
Study: 3898701

Group type: EXPERIMENTAL
Intervention: Ciramadol 60 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ciramadol 30 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Morphine 10 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ciramadol
Number of subjects: 100
Study: 30255760

Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine (NAC) 600 mg twice daily for 12 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 29806738

Group type: EXPERIMENTAL
Intervention: 1 g powdered brown mustard
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cooked broccoli alone
Number of subjects: 12
Study: 27663941

Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin (IVIG) 1 g/kg/day on 2 consecutive days
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Open-label IVIG (for nonresponders)
Number of subjects: 35
Study: 24469371

Group type: EXPERIMENTAL
Intervention: Traditional apicoectomy (group 1)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Modern microsurgical apicoectomy using burns for osteotomy (group 2)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Modern microsurgical apicoectomy using piezo-osteotomy (group 3)
Number of subjects: 843

Group type: COMPARATOR
Intervention: Silver amalgam root-end filling material
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate root-end filling material
Number of subjects: 843
Study: 22699884

Group type: EXPERIMENTAL
Intervention: Hospital-based work support intervention
Number of subjects: 65
Study: 19346218

Group type: EXPERIMENTAL
Intervention: Ariva
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Marlboro Snus
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Camel Snus
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Commit nicotine lozenge (2 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: own brand cigarettes
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Quest cigarettes
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: sham smoking (unlit cigarette)
Number of subjects: 28
Study: 18035135

Group type: EXPERIMENTAL
Intervention: Right lateral position (RLP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Right lateral position (RLP) followed by left lateral position (LLP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Right lateral position (RLP) first
Number of subjects: 10
Study: 16109319

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 4937

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4937
Study: 11965579

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b, 1 x 10(6) U/d (Group A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b, 3 x 10(6) U three times weekly (Group B)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b, 1 x 10(6) U/d, plus ribavirin, 400 mg twice daily (Group C)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study: 10099140

Group type: EXPERIMENTAL
Intervention: Propranolol therapy (dose sufficient to decrease baseline heart rate by 25%)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (performed weekly until varices were obliterated)
Number of subjects: 89
Study: 7739944

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 21
Study: 1675042

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 micrograms.kg‐1
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.3 micrograms.kg‐1
Number of subjects: 96

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 96

Group type: COMPARATOR
Intervention: Fentanyl 2.0 micrograms.kg‐1
Number of subjects: 96
Study: 399787

Group type: EXPERIMENTAL
Intervention: Simeticon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31363328

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 81

Group type: COMPARATOR
Intervention: No stress ulcer prophylaxis (control group)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combination of risk factors (APACHE II >18, age >65, mechanical ventilation, sedation)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: ICU stay >10 days
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cardiovascular disease as underlying disorder
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Sedation and previous antibiotic therapy
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Higher values of gastric content pH
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Colonization with Acinetobacter spp.
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Risk factors that accelerated occurrence of HAP
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combination of risk factors
Number of subjects: 81
Study: 27297097

Group type: EXPERIMENTAL
Intervention: Cytological surveillance
Number of subjects: 3399

Group type: COMPARATOR
Intervention: Initial colposcopy
Number of subjects: 3399
Study: 25139063

Group type: EXPERIMENTAL
Intervention: Standardized sustained muscular pain challenge
Number of subjects: 34
Study: 23562192

Group type: EXPERIMENTAL
Intervention: Montelukast and Levocetirizine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Montelukast and Desloratadine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21276671

Group type: EXPERIMENTAL
Intervention: Nasal Cannula (NC) group, weaned off NCPAP when FiO(2) was ≤0.30 to NC (2 L/min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-NC group, kept on NCPAP until FiO(2)=0.21 for 24 h, then weaned off NCPAP
Number of subjects: 60
Study: 19351943

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT), n = 70
Number of subjects: 134

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC), n = 64
Number of subjects: 134
Study: 16411996

Group type: EXPERIMENTAL
Intervention: Kiwi Omnicup
Number of subjects: 404

Group type: COMPARATOR
Intervention: Conventional vacuum cups
Number of subjects: 404
Study: 15319494

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 3224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3224
Study: 11747915

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Fourth dose of RTS,S/AS02
Number of subjects: 306

Group type: COMPARATOR
Intervention: Rabies vaccine (control)
Number of subjects: 306
Study: 9406807

Group type: EXPERIMENTAL
Intervention: Sunscreen applied directly onto the skin or onto a piece of quartz fixed to the skin before UV exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no sunscreen applied)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Earlier study with the same sunscreen
Number of subjects: 0
Study: 8376638

Group type: EXPERIMENTAL
Intervention: School-based primary prevention psychological program (cognitive-behavioral modification principles)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 237
Study: 3777838

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen inhalational sedation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Local anaesthesia alone
Number of subjects: 30
Study: 31597320

Group type: EXPERIMENTAL
Intervention: Allogenic Faecal Microbiota Transfer (FMT)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Autologous Faecal Microbiota Transfer (FMT)
Number of subjects: 17
Study: 29976533

Group type: EXPERIMENTAL
Intervention: Gabapentin (GABA group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dexchlorpheniramine (DEX group)
Number of subjects: 60
Study: 25406227

Group type: EXPERIMENTAL
Intervention: Sodium supplementation (4 mEq/kg/d)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sodium supplementation
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sterile water (placebo)
Number of subjects: 53
Study: 24597683

Group type: EXPERIMENTAL
Intervention: Integrated online psychosocial assessment and cognitive behavior therapy (CBT)
Number of subjects: 816

Group type: COMPARATOR
Intervention: Usual prenatal care (no formal screening or specialized care)
Number of subjects: 816
Study: 22314126

Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (IR-MPH)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Osmotically controlled-release oral delivery system methylphenidate (OROS-MPH)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: IR-MPH to IR-MPH
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: IR-MPH to OROS-MPH
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: OROS-MPH to IR-MPH
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: OROS-MPH to OROS-MPH
Number of subjects: 26
Study: 20195162

Group type: EXPERIMENTAL
Intervention: SQT-8 (8 days)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: SQT-10 (10 days)
Number of subjects: 270

Group type: COMPARATOR
Intervention: STT (7 days)
Number of subjects: 270
Study: 19000095

Group type: EXPERIMENTAL
Intervention: Rituximab (Rtx) treatment
Number of subjects: 0
Study: 15894697

Group type: EXPERIMENTAL
Intervention: Unconditional incentive ($10 with survey)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Conditional incentive ($10 upon receipt of completed survey)
Number of subjects: 397
Study: 11842038

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (LI; 400 kcal at 40% of maximal oxygen consumption)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (HI; 400 kcal at 70% of maximal oxygen consumption)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sedentary day (Con)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Comparison of men and women
Number of subjects: 16
Study: 10510144

Group type: EXPERIMENTAL
Intervention: L‐758 298 (0.25 mg, 1 mg, 5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: L‐758 298 (1.43 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8526962

Group type: COMPARATOR
Intervention: High fresh gas flow rate (6.0 L/min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Minimal fresh gas flow rate (0.6 L/min)
Number of subjects: 24
Study: 1873687

Group type: EXPERIMENTAL
Intervention: Cromakalim
Number of subjects: 0
Study: 6790048

Group type: COMPARATOR
Intervention: Oxprenolol (40 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intensive speech therapy using slowed-speech and relaxation technique
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Maintenance speech therapy
Number of subjects: 31
Study: 29564507

Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg for <65 years, 300 mg for >65 years)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 27120194

Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fixed-bearing TKA
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study: 26084792

Group type: EXPERIMENTAL
Intervention: Atorvastatin 5 mg/day
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg/day
Number of subjects: 146
Study: 25060414

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists (MRAs)
Number of subjects: 1998

Group type: COMPARATOR
Intervention: Not applicable (placebo arm)
Number of subjects: 1998
Study: 22194326

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 18
Study: 19542796

Group type: EXPERIMENTAL
Intervention: Vapocoolant alone
Number of subjects: 57

Group type: COMPARATOR
Intervention: Typical care
Number of subjects: 57
Study: 17286630

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A reconstituted in lidocaine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Botulinum toxin A reconstituted in normal saline
Number of subjects: 29
Study: 15631562

Group type: EXPERIMENTAL
Intervention: lay health advisor (promotora) plus tailored print materials
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: tailored print materials only (tailored)
Number of subjects: 357

Group type: COMPARATOR
Intervention: off-the-shelf print materials (control)
Number of subjects: 357
Study: 11840078

Group type: EXPERIMENTAL
Intervention: d4T/NVP/RTV
Number of subjects: 48

Group type: COMPARATOR
Intervention: d4T/RTV
Number of subjects: 48

Group type: COMPARATOR
Intervention: ZDV/3TC/RTV
Number of subjects: 48
Study: 14666752

Group type: EXPERIMENTAL
Intervention: Glucantime
Number of subjects: 109

Group type: COMPARATOR
Intervention: Local treatment (eosin 5% and alcohol 95%)
Number of subjects: 109
Study: 8625054

Group type: COMPARATOR
Intervention: Metoclopramide (0.5 mg/kg) plus methylprednisolone (125 mg)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg) orally
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg) orally plus methylprednisolone (125 mg)
Number of subjects: 262
Study: 2285628

Group type: EXPERIMENTAL
Intervention: Felodipine, 10 mg twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7173301

Group type: EXPERIMENTAL
Intervention: Prednisolone (8 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Betamethasone (1 mg/day)
Number of subjects: 20
Study: 31996940

Group type: EXPERIMENTAL
Intervention: 1 mg per 70-kg body weight dose of nicotine delivered over 1 min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1 mg per 70-kg body weight dose of nicotine delivered over 5 min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1 mg per 70-kg body weight dose of nicotine delivered over 10 min
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 18
Study: 28135841

Group type: EXPERIMENTAL
Intervention: Pravastatin for secondary stroke prevention
Number of subjects: 0
Study: 26876688

Group type: EXPERIMENTAL
Intervention: 3D-QCA
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2D-QCA
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2D-QCA and 3D-QCA
Number of subjects: 90
Study: 23512260

Group type: EXPERIMENTAL
Intervention: Protocol 1 (P1) - customized contrast dose based on time-attenuation response (0.3 ml/kg body weight)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Protocol 2 (P2) - tailored contrast dose based on body weight (0.7 ml/kg body weight)
Number of subjects: 60